Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients

By P. Bedossa, C. Poitou, N. Veyrie, J. Bouillot, A. Basdevant, V. Paradis, J. Tordjman, Karine Clément. Hepatology, 2012

807 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/3a91442496adfe67b0fa55a8b7e75f1a43cb82f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. Q. Anstee
4. K. Cusi
5. A. Sanyal
6. G. Targher
7. Megan H. Bair-Merritt
8. R. Loomba

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. A. Sanyal
4. K. Cusi
5. E. Brunt
6. Q. Anstee
7. J. Lavine
8. N. Chalasani

In Hepatology

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. E. Brunt
6. Q. Anstee
7. J. Clark
8. R. Loomba

Citations in the corpus

• Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. (2015, neutral): “07), NAS score (median [IQR] 5 [4-5] vs.”
• Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. (2017, methodology): “[15] The FLIP algorithm was used to define presence of NASH.”
• Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. (2019, background): “in Patients With Nonalcoholic Fatty Liver Disease CL IN IC AL LI VE R Peter J. Eddowes,1,2,3,4 Magali Sasso,5 Michael Allison,6 Emmanouil Tsochatzis,7 Quentin M. Anstee,8 David Sheridan,9 Indra N. Guha,4 Jeremy F. Cobbold,10 Jonathan J. Deeks,11 Valérie Paradis,12 Pierre Bedossa,12 and Philip N. New”
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023, neutral): “The histological classi fi cation was further expanded on by various scoring systems categorising steatosis, disease activity, and fi brosis [2 − 4].”
• Cellular senescence drives age-dependent hepatic steatosis (2017, neutral): “The grade of steatosis (0–3), disease activity, including semi-quantification of lobular inflammation and hepatocyte ballooning, and stage of fibrosis (0–4) were assessed according to Kleiner et al. 48 and Bedossa et al. 49 .”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, methodology): “Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease.”